Navigation Links
Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
Date:11/28/2007

Summary: Genmab and GlaxoSmithKline Have Completed Recruitment of 66 CLL Patients Respectively to Both Study Groups in a Pivotal Study of ofatumumab

COPENHAGEN, Denmark, November 28 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today recruitment of 132 patients has been completed in a pivotal study of ofatumumab (HuMax-CD20(R)) for the treatment of refractory chronic lymphocytic leukemia (CLL). This cohort comprises 66 patients who are refractory to both fludarabine and alemtuzumab and 66 fludarabine refractory patients who are considered inappropriate candidates for alemtuzumab due to bulky tumor in their lymph nodes. An interim analysis will be conducted on this cohort when 24 week efficacy data are available. The study will remain open for recruitment in order to collect additional safety and efficacy data.

Ofatumumab is an investigational, fully human, next generation monoclonal antibody that targets a unique epitope of the CD20 receptor on the surface of b-cells. This epitope is different to the other anti-CD20 antibodies currently available or in development. Ofatumumab is being developed under a co-development and commercialization agreement between Genmab and GlaxoSmithKline.

"We look forward to seeing the study results of the interim analysis from both patient groups. It is our hope, due to the high unmet need amongst these patients, that registration may be possible in each indication, depending on the data generated and ongoing discussions with the regulatory authorities. Recruitment will continue to the trial," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.

About the study

The study includes CLL patients who are refractory to both fludarabine and alemtuzumab and patients who are refractory to fludarabine who are considered inappropriate candidates for alemtuzumab due to bulky tumor in their lymph nodes. Each group will be analyzed separately and it is hoped that, registration of ofatum
'/>"/>

SOURCE Genmab A/S
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... CLARA, Calif. , July 29, 2014 /PRNewswire-iReach/ ... services agreement with FORMA Therapeutics, Inc., to provide ... and proprietary fragment-based lead discovery platform for novel ... really excited about the opportunity to work with ... fields of epigenetics and protein homeostasis. FORMA Therapeutics, ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 July ... vaccine pioneer in the biotechnology industry, announced that ... Coast Securities, Inc. to explore financing opportunities that ... technology, a breakthrough vaccine platform with the potential ... The company exclusively licensed the well-established LAMP platform ...
(Date:7/29/2014)... Quorum Review IRB, the industry ... accreditation by the International Association of Six ... Sigma Deployment Program. The citation recognizes robust organizational ... Quorum’s Lean Six Sigma program was evaluated by ... The designation is a public statement of excellence ...
(Date:7/29/2014)... Boston, MA (PRWEB) July 29, 2014 ... the Library of Congress was recently awarded to Juliana ... in Stoneham, MA, for their project, “From an Egg, ... from among 3,000 final entries for the National History ... more than 300 historians and educators in Washington, D.C. ...
Breaking Biology Technology:Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 2Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 3In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 3
... Incorporated (Nasdaq: ARAY ), a global leader in ... results for its second quarter of fiscal 2011, ended December ... closes. A conference call to review the results ... be hosted by Euan S. Thomson, Ph.D., president and chief ...
... Registration is now open for StemCONN 2011. ... in stem cell research, will take place Tuesday, March ... session) and the UConn Health Center (commercial session and ... at http://stemconn.org/ . StemCONN 2011 will ...
... Md., Jan. 13, 2011 Celsion Corporation (Nasdaq: ... to the development and commercialization of innovative oncology drugs, ... securities purchase agreement with a select group of institutional ... to sell 5,000 shares of 8% redeemable convertible preferred ...
Cached Biology Technology:Accuray Incorporated to Report Financial Results for Second Quarter of Fiscal 2011 2Celsion Corporation Announces Convertible Preferred Stock Financing and Amended License Agreement for Aggregate Gross Proceeds of up to $9 Million 2Celsion Corporation Announces Convertible Preferred Stock Financing and Amended License Agreement for Aggregate Gross Proceeds of up to $9 Million 3Celsion Corporation Announces Convertible Preferred Stock Financing and Amended License Agreement for Aggregate Gross Proceeds of up to $9 Million 4
(Date:7/29/2014)... (UM SOD) and Medicine (UM SOM) jointly announced ... million grant award from the National Institute of ... Institutes of Health to study the causes, prevention ... which renews a previous $12 million five-year NIAID-funded ... research by studying chlamydial and gonorrheal diseases as ...
(Date:7/29/2014)... to go and almost 2500 registered participants, the final ... The event, a joint venture between the Federation of ... for Biochemistry and Molecular Biology (SFBBM), will take place ... the Palais des Congrs in Paris, France. , The ... life sciences in Europe this year. It features more ...
(Date:7/29/2014)... it affects 1 in 100,000 people characterized by ... its cause remains unknown, a new study by a team ... Bonn in Germany and other European institutions confirms for the ... published on 6 July in Nature Genetics , is ... we swallow, a sphincter in the lower esophagus opens, allowing ...
Breaking Biology News(10 mins):University of Maryland Schools of Dentistry and Medicine receive NIH grant 2University of Maryland Schools of Dentistry and Medicine receive NIH grant 3University of Maryland Schools of Dentistry and Medicine receive NIH grant 4Counting down to FEBS-EMBO 2014 in Paris, France 2Mysterious esophagus disease is autoimmune after all 2
... Entomological Society of America (ESA) invites scientists to submit ... which will be held in Knoxville, Tennessee, November 11-14, ... This year,s theme is "A Global Society for ... reflect this theme, if possible. The deadline for ...
... Oilsands development uses a vast amount of water and ... the toxins and metals leftover from extracting and upgrading ... a lightening rod for controversy and a significant risk ... at the University of Calgary and engineers at the ...
... Hay fever (runny nose, sneezing, itchy eyes) is caused by ... These tiny grains bring misery to sufferers through spring and ... weather reports to help sufferers prepare. However new research published ... Allergy shows that, regardless of medication and other allergies, ...
Cached Biology News:Researchers develop new method of cleaning toxins from the oilsands 2Get ready for spring - hay fever worse in spring than summer 2
Purified Mouse anti-Hu LAT (pY226) Storage Temperature: Refrigerate(2 to 8C)...
Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile, Molecular Biology Grade...
... the most comprehensive, cost-effective solution to ... incorporated unprecedented quality into both our ... proven detection chemistries and antibodies that ... protocol. It also includes our competitively ...
...
Biology Products: